Elicera Therapeutics
1.345 SEK +11.16%1 investor is following this company
Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
ELIC
Daily low / high price
1.205 / 1.355
SEK
Market cap
47.2M SEK
Turnover
273.21K SEK
Volume
216K
Latest videos
Financial calendar
Interim report
2024-08-29
Interim report
2024-11-14
Annual report
2025-02-13
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Magnus Essand | 16.8 % | 16.8 % |
Di Yu | 16.7 % | 16.7 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Elicera Therapeutics: BioStock: Elicera inleder samarbete med China Medical University för cancerstudie
Elicera Therapeutics ingår prekliniskt samarbetsavtal med China Medical University för utvecklingen av ELC-201
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools